| Autumn Keiser, | |
|
1501 E 10th St, Atlantic, IA 50022-1936 | |
| (712) 243-3250 | |
| (712) 243-7587 |
| Full Name | Autumn Keiser |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 9 Years |
| Location | 1501 E 10th St, Atlantic, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043694847 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | R-10410 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospice Of The Midwest, Llc | Johnston, IA | Hospice |
| Cass County Memorial Hospital | Atlantic, IA | Hospital |
| Myrtue Medical Center | Harlan, IA | Hospital |
| The Nebraska Medical Center | Omaha, NE | Hospital |
| Salem Lutheran Home | Elk horn, IA | Nursing home |
| Heritage House | Atlantic, IA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cass County Memorial Hospital | 5294634994 | 59 |
News Archive
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
During the years 1976 through 1980, 15% of U.S. adults were obese. Today, about 40% of adults are obese. Another 33% are overweight.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.
Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.
› Verified 6 days ago
| Entity Name | Cass County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861597122 PECOS PAC ID: 5294634994 Enrollment ID: O20031231000681 |
News Archive
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
During the years 1976 through 1980, 15% of U.S. adults were obese. Today, about 40% of adults are obese. Another 33% are overweight.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.
Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.
› Verified 6 days ago
| Entity Name | Siouxland Medical Education Foundation, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336127828 PECOS PAC ID: 6608761101 Enrollment ID: O20040216000191 |
News Archive
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
During the years 1976 through 1980, 15% of U.S. adults were obese. Today, about 40% of adults are obese. Another 33% are overweight.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.
Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.
› Verified 6 days ago
| Entity Name | Northwest Iowa Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215962550 PECOS PAC ID: 0749198026 Enrollment ID: O20040217000619 |
News Archive
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
During the years 1976 through 1980, 15% of U.S. adults were obese. Today, about 40% of adults are obese. Another 33% are overweight.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.
Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.
› Verified 6 days ago
| Entity Name | Northwest Iowa Emergency Physicians, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871519207 PECOS PAC ID: 3971495797 Enrollment ID: O20040326000817 |
News Archive
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
During the years 1976 through 1980, 15% of U.S. adults were obese. Today, about 40% of adults are obese. Another 33% are overweight.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.
Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Autumn Keiser, 1501 E 10th St, Atlantic, IA 50022-1936 Ph: (712) 250-8047 | Autumn Keiser, 1501 E 10th St, Atlantic, IA 50022-1936 Ph: (712) 243-3250 |
News Archive
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause consumers to doubt the value of calcium supplements for maintaining bone health.
During the years 1976 through 1980, 15% of U.S. adults were obese. Today, about 40% of adults are obese. Another 33% are overweight.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.
Results from two clinical trials show that patients with early-stage breast cancer who received trastuzumab (Herceptin) in combination with chemotherapy had a 52 percent decrease in risk for breast cancer recurrence, compared with patients who received the same chemotherapy without the drug. The difference is statistically highly significant.
› Verified 6 days ago
Adam Joel Verhoef, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1501 E 10th St, Atlantic, IA 50022 Phone: 712-243-3250 | |
Emily Anne Wittrock, RN, BSN, MSN, FNP-C Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1501 E 10th St, Atlantic, IA 50022 Phone: 712-243-3250 | |
Todd C. Bean, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1501 E 10th St, Atlantic, IA 50022 Phone: 712-243-2850 Fax: 712-243-7423 | |
Elaine K. Berry, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1501 E 10th St, Atlantic, IA 50022 Phone: 712-243-2850 Fax: 712-243-7423 | |
Patricia Lynn Goodemote, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1501 E 10th St, Atlantic, IA 50022 Phone: 712-243-7430 | |
Angela B Weppler, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1501 E 10th St, Atlantic, IA 50022 Phone: 712-243-2850 Fax: 712-243-7423 |